3-D Matrix,Ltd. Q4 FY2025 earnings call

• Financial Performance

  • Full year total revenue hit 6.934 billion yen, a 51% YoY increase. A 1.1 billion yen operating loss was recorded, which includes a one-time 570 million yen total impairment charge (350 million yen for excess non-core product inventory, 220 million yen for unuseable raw peptide material from a secondary supplier). Excluding this one-time charge, operating loss improved 200 million yen to 588 million yen, and the fourth quarter turned a small operating profit on an adjusted basis.
  • A 1 billion yen non-cash foreign exchange loss from yen appreciation widened net and ordinary loss; this is a purely accounting impact with no associated cash outflow. Excluding foreign exchange impacts, ordinary and net loss improved roughly 800 million yen and 1.2 billion yen YoY, respectively.
  • All 2024 new share warrants were exercised, raising 2.9 billion yen in cash, providing sufficient near-term liquidity. Fixed liabilities decreased by more than 1.2 billion yen following conversion and partial redemption of convertible bonds, with remaining convertible bond conversion expected to continue.

• Regional Sales Operations

  • The U.S. sales team achieved above-expected growth and profit generation, with sales force expansion directly translating to higher order volume, and the GI business base strengthening steadily month-over-month. The U.S. GI market still has substantial room for further growth.
  • Europe's urology segment saw strong growth in radiation cystitis and benign prostatic hyperplasia indications, with significant remaining upside. The company will prioritize returning Germany's GI segment to growth through increased direct on-the-ground leadership, and target full-year operating profit for the European region in 2025.

• Pipeline and Product Development

  • Multiple late-stage projects are moving toward U.S. regulatory submissions: pediatric cardiac surgery hemorrhage control has completed clinical data collection, pharyngeal hemorrhage control has completed clinical data collection, and prostatic resection hemorrhage control is preparing submission based on test marketing collaboration with a surgical robotics company.
  • Mucosal wound healing just completed 510(k) submission to the U.S. FDA, with approval expected by October 2025. Neurosurgical hemorrhage control approval in Europe has been delayed and is now expected in summer 2025.
  • The previously approved PureLift submucosal injection device is preparing for scaled production at a new manufacturing site to lower costs before re-launch. Early-stage clinical and preclinical research is ongoing for inflammatory bowel disease, radiation therapy spacers, esophageal stricture prevention, dysphagia prevention, bone graft fillers, and miRNA drug delivery for mesothelioma and head and neck cancer.

• Strategic Priorities

  • The company maintains its existing mid-term strategy focused on the GI segment, prioritizing operating profit improvement over unlimited revenue growth, and targeting growth without expanding losses. Growth is primarily planned from the GI segment, with emerging segments like ENT and urology counted as upside upside if they outperform expectations.

Geographic segments:

1. United States: Grew more than 200% year-over-year, outperforming expectations, driven by strong demand and efficient sales team expansion in the core gastroenterology endoscopy (GI) segment.
2. Europe: 21% YoY revenue growth, below the 29% growth target. Growth was held back by underperformance in Germany's GI segment (where the company had limited on-the-ground sales presence) and intentional flatlining of sales from the discontinued cardiac segment investment. Regions with direct on-the-ground sales presence (such as the UK) achieved 45% YoY GI growth. The urology segment saw strong growth, and Europe achieved Q4 operating profitability, hitting a key milestone.
3. Japan: Achieved 37% YoY revenue growth, meeting full-year budget. Growth is now driven by increased usage from existing customers, as large hospital market penetration is already high and new customer acquisition growth is slowing.
4. Australia: 10% YoY revenue growth, below budget, due to multiple rounds of government-mandated price cuts and insurance category reclassification that lowered product pricing. Unit sales hit an all-time high and met volume targets despite the pricing pressure.

Product segments: The core PuraStat (GI) product drove the majority of revenue growth across all regions. Overstocked, unsold inventory of non-core products PuraBond (cardiac) and PuraSheild (ENT) held in Europe resulted in a 350 million yen product valuation impairment charge. The urology and ENT segments are emerging as new growth pillars, with the urology segment already seeing strong early uptake in Europe.

• Full-year 2025 revenue is guided to 9.283 billion yen, representing 34% YoY growth, maintained from the prior mid-term plan. Full-year operating profit is guided to 400 million yen, meaning the company will achieve its target of full-year operating profitability in 2025 as previously planned.
• By region: U.S. revenue is guided to 55% YoY growth, with an absolute annual increase matching 2024, which is considered achievable after Q4 2024 sales force expansion. Europe is guided to 21% YoY growth, matching 2024's growth rate with no major additional sales resource investment. Japan is guided to 8% YoY growth, reflecting the mature market and slowing new customer acquisition growth.
• Quarterly breakdown: A small Q1 operating deficit is expected due to start-of-year cost increases (such as salary adjustments), with operating profitability returning and normalizing from Q2 onward, growing to an 11.2% operating margin in Q4 2025.
• The mid-term plan targets continued 30% YoY growth in 2026 and 20% YoY growth in 2027, reaching nearly 150 billion yen in total revenue after three years, with operating profit margin approaching 20% by the end of the period. The core target of operating profit profitability in 2025 is unchanged from the prior mid-term plan.
• Multiple new product approvals are expected in 2025, including European approval for neurosurgical hemorrhage control in summer 2025, U.S. approval for mucosal wound healing in H2 2025, and U.S. regulatory submissions for pharyngeal hemorrhage control and prostatic resection hemorrhage control in H2 2025.

• Excess inventory buildup for non-core PuraBond and PuraSheild occurred after the company shifted sales resources to focus on the core GI segment, resulting in a material 350 million yen one-time impairment charge that caused the full-year operating result to miss prior expectations.
• Aged peptide raw material sourced from a secondary supplier carries quality assurance uncertainty due to changes in the supplier's organization, resulting in an additional 220 million yen one-time impairment charge.
• The company's foreign currency-denominated loans to overseas subsidiaries create material non-cash foreign exchange gain/loss volatility that can significantly impact reported ordinary and net profit during periods of yen exchange rate movement.
• Germany's GI segment has underperformed due to the company's lack of direct on-the-ground sales control, creating regional revenue growth risk if the planned direct management overhaul does not deliver improved growth.
• New product regulatory approvals can face unanticipated delays, as seen with the delayed European approval for neurosurgical hemorrhage control, which shifts expected revenue and approval milestones to later periods.

The provided earnings call transcript does not include a transcribed Question and Answer section.